Controversial blood transfusions to delay old age that are fashionable among US millionaires

Can the younger's blood rejuvenate the elders? Millionaires not only believe in this hypothesis, how they are paying for transfusions for that purpose in the United States.

Who's behind that futuristic-looking idea and sci-fi airs are Silicon Valley companies, the heart of California technology.

Peter Thiel, cofounder of online payment company PayPal, is rumored to be spending

SPL Tests on promising mice show, but believe it is still too early to use parabiosis in humans

The technique, known as parabiosis or physiological and anatomical union of two organisms, has become the working base of several companies in California that try to replicate the rejuvenating effects in humans.

But at the same time they try to revolutionize science, they attract controversy and much discussion.

Clinical trial

For the doctor Jesse Karmazin, the future is now.

In 2016, Karmazin, who graduated from Stanford University, founded Ambrosia, a startup that investigates the blood effects of younger people in the fight against aging diseases.

"We have just completed the first clinical trial. We are going to do more studies, but the results so far are good," Karmazin told BBC World.

"We believe that the treatment is successful, which reverses aging and works for a number of ills associated with old age, such as heart disease, diabetes and Alzheimer's," he adds.

From the test mentioned by Karmazin, 150 people between the ages of 35 and 80 participated, who paid US $ 8 thousand (about R $ 27,000) each for the treatment.

"It was a simple transfusion," the doctor explains. "We get the excess plasma from blood banks, which have a lot. We only use plasma, which is the blood fluid, without the cells," he says.

He explains that people go to the clinic - Ambrosia has one in California and another in Florida - and they get the young plasma in the vein